News searcher
ROVI recibe la opinión positiva del CHMP para Okedi® como tratamiento de la esquizofrenia
On the basis of the CHMP’s recommendation, the European Commission will issue its decision on the approval of...
4 min
17 Dec, 2021
2021 Capital Markets Day presentation
ROVI updates its strategy in a meeting with shareholders, investors and analysts
1 min
16 Nov, 2021
First Nine Months 2021 Results Press Release
ROVI reports operating revenue growth of 53% and doubles its Ebitda
5 min
03 Nov, 2021
ROVI Share Buyback Program
ROVI reported the commencement by the Company, effective as of today, 3 November 2021, of a share buyback program
4 min
03 Nov, 2021
The FDA delays its decision on Risperidone ISM®
Delay in the decision on the granting of marketing authorisation for Risperidone ISM® by the U.S. Food and Drug...
2 min
21 Oct, 2021
ROVI informa del comunicado conjunto de Moderna y Takeda en relación con la investigación sobre los lotes bloqueados de la vacuna
Laboratorios Farmacéuticos ROVI, S.A. informs of the joint press release from Moderna and Takeda regarding the...
4 min
01 Sep, 2021
Laboratorios Farmacéuticos ROVI, S.A. has announced that a formal investigation is continuing to determine what...
2 min
29 Aug, 2021
Laboratorios Farmacéuticos ROVI, S.A. has announced that a formal investigation is continuing to determine what...
2 min
29 Aug, 2021
Laboratorios Farmacéuticos ROVI, S.A. has announced that an investigation is underway in relation to the reported...
1 min
26 Aug, 2021